Matica Bio and Sartorius have entered a joint research agreement to develop advanced viral vector manufacturing technology. Matica Biotechnology, a contract development manufacturing organization (CDMO) that specializes in the clinical and commercial production of cell and gene therapies (CGTs), will work on various studies with German life sciences firm Sartorius to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large scale vector production. According to Matica, together both companies will tackle the challenges associated…

Hansoh Pharma will use Silence Therapeutics’ mRNAi GOLD platform to develop three undisclosed short interfering ribonucleic acids (siRNAs). According to RNA interference biotech company Silence, its mRNAi GOLD platform is  “designed to accurately target and ‘silence’ specific disease-associated genes in liver cells by using the body’s natural process of RNA interference (RNAi).” Under the terms of the agreement, Hansoh will have the exclusive option to license rights to two targets in Hong Kong, Greater China, Macau, and Taiwan following Phase…

The International Society for Cell and Gene Therapy (ISCT) and the National Science Foundation (NSF) have partnered to provide training to upskill personnel. Led by the Georgia Institute of Technology, the global collaboration between ISCT and NSF’s Engineering Research Center for Cell Manufacturing Technologies (CMaT) aims to bridge the critical skills gap in the cell and gene therapy (CGT) industry by delivering educational programs. The joint-training program entitled ‘‘Workforce Development in Biomanufacturing – A Global Partnership with ISCT and CMaT”,…

BioCentriq’s laboratories will be equipped with Terumo’s technologies to accelerate the adoption of automated production for cell and gene therapies. Apheresis services firm Terumo Blood and Cell Technologies and cell and gene therapy contract development manufacturing organization (CDMO) BioCentriq have entered a strategic collaboration to bring cell and gene therapies (CGT) to individuals more quickly and cheaper. “This agreement will expand customer reach by introducing early-stage CGT researchers and developers to the benefits of manufacturing automation and demonstrating how to…